On the effect of the injection of potassium phosphate in vivo inducing the precipitation of serum calcium with inorganic phosphate. by AMARO, G. C. et al.
Int J Physiol Pathophysiol Pharmacol 2013;5(4):239-247
www.ijppp.org /ISSN:1944-8171/IJPPP1310003
Original Article
On the effect of the injection of potassium phosphate  
in vivo inducing the precipitation of serum calcium  
with inorganic phosphate
Alcimar B Soares1, José G Ticianeli1, Letícia B M Soares2, George Amaro3
1Laboratory of Biomedical Engineering, Federal University of Uberlândia, Uberlândia, MG, Brazil; 2Nephrology Ser-
vice, General Hospital, Federal University of Uberlândia, Uberlândia, MG, Brazil; 3Brazilian Agricultural Research 
Company, Boa Vista, RR, Brazil
Received October 25, 2013; Accepted November 30, 2013; Epub December 15, 2013; Published December 30, 
2013
Abstract: High concentrations of inorganic phosphate (Pi) resulted from the hydrolysis of ATP is strongly associated 
to the weakness of the contractile mechanism of muscles due to its attractiveness to calcium. The majority of the 
experiments to study such effect are conducted in vitro. This work investigates the effects of different concentra-
tions of Pi, induced by the injection of potassium phosphate in live animals, in the precipitation with serum calcium 
and the generation of calcium phosphate composites. The experiments were also designed to find out the ideal 
amount of potassium phosphate to induce an effective reaction. Potassium phosphate was injected in Wistar rats, 
randomly separated and distributed into seven groups. Group I was injected with 0.5 ml of saline solution (con-
trol) and groups II through VII were injected with 0.5, 1.5, 2.5, 5.0, 7.5 and 10.0 mg/kg of potassium phosphate, 
respectively. Blood collected from the inferior vena cava was submitted to biochemical analyses to measure the 
concentrations of calcium, Pi, urea and creatinine. The results showed that Pi, induced by the injection of potas-
sium phosphate in live animals, causes precipitation with serum calcium, with statistically significant differences 
between the control and the treatment groups for doses up to 5.0 mg/kg. No statistically significant differences 
were found between the different doses and the concentration of urea and creatinine in the plasma. We conclude 
that potassium phosphate can be used to induce serum calcium precipitation in-vivo, with minor effects on other 
physiological variables, and the ideal dose to do so is 5.0 mg/kg.
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Introduction
The effect of extracellular calcium and inorgan-
ic phosphate (Pi) on various aspects of the cel-
lular mechanism has been the object of study 
of many research groups over the past decades 
[1-7]. Special attention has been devoted to the 
role of those substances in the underlying pro-
cess of skeletal muscle contraction that begins 
with the release of a series of action potentials, 
promoting cell membrane depolarization and 
the release of calcium ions from the sarcoplas-
mic reticulum terminal [8-10]. Since the hydro-
lysis of adenosine triphosphate (ATP) is also 
required to provide energy and maintain the 
contraction, it is expected that the amount of 
ATP and its hydrolysis must be directly propor-
tional to the demands of each contraction. 
Depending on the intensity of the contraction, 
the hydrolysis of ATP can increase the concen-
tration of cytoplasmic Pi up to 30 mM [11-13]. 
Although other biochemicals, including phos-
phocreatine (PCr), creatine, glucose 6-P and 
lactate also play an important role in the regula-
tion of muscle contraction and power genera-
tion, high concentration of cytoplasmic Pi has 
been reported as one of the most important 
element contributing to fatigue and reduction of 
power [5, 11, 13, 14]. This can be explained by 
the attractiveness of Pi to calcium ions (Ca2+), 
released by the sarcoplasmic reticulum (SR), 
leading to the formation of an insoluble sub-
stance called calcium phosphate (CaPi) and 
reducing the quantities of Pi and Ca2+ required 
to sustain the contraction [3].
Fryer et al were the first to suggest that Pi could 
enter the sarcoplasmic reticulum and precipi-
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tate Ca2+, forming CaPi and rapidly reducing the 
amount of calcium ions released, contributing 
to muscle fatigue [1]. Other works can also be 
found in the literature describing the effects of 
Pi reacting with Ca2+ released by the sarcoplas-
mic reticulum (SR) [4, 15-18]. However, since 
the majority of those experiments were carried 
out in vitro, it is possible that we are missing 
important metabolic reactions and substanc-
es, that could not be found or replicated in vitro 
but would play a significant role in the process 
of muscle contraction. Therefore, one can infer 
that the results of those surveys, while worthy 
of attention, are somehow limited to specific 
areas of interest. In fact, Fryer et al conclude 
that the omission of some possible in vivo reac-
tions did not allow them to clearly establish if 
the decreased muscle strength was only due to 
precipitation of CaPi within the sarcoplasmic 
reticulum, or due to the loss of Ca2+ by the SR 
[1]. For example, cytoplasmic Pi can increase 
the probability of opening SR’s ryanodine recep-
tors (RyRs) [12, 19, 20]. RyRs are vital for mus-
cle contraction since they are responsible for 
releasing Ca2+ into the cytosol [7, 21]. Hence, if 
cytoplasmic Pi can change the probability of 
opening RyRs channels, it can interfere with 
the whole process of muscle contraction. Also, 
cytoplasmic Pi may enter the SR and bind to 
Ca2+, forming CaPi, further reducing the amount 
of releasable Ca2+ [6]. Nevertheless, it is possi-
ble that muscle strength is not affected by a 
significant reduction in Ca2+ available in the SR, 
since its endogenous contents of calcium (~1.1 
mmol/l) may be much greater than necessary 
to fully activate the contractile mechanism [2, 
9]. However, this is yet to be demonstrated.
In this article, we propose a method that can 
potentially be used to verify some of those 
important reactions in vivo. We investigate 
whether inorganic phosphate, induced by the 
injection of potassium phosphate (K3PO4) in live 
animals, causes serum calcium precipitation, 
generating the insoluble calcium phosphate 
and, if so, what is the ideal amount to do it 
effectively. If the method proves to be feasible, 
without prejudice to the animal’s health, it can 
contribute to the opening of new frontiers to the 
study of muscle fatigue in animals or humans. 
Materials and methods
Animals
Male rats of the Wistar strain, with an average 
age of 90 to 120 days, weighing between 50 
and 150 gr, maintained on food and water ad 
libitum, housed in cages of white polyethylene 
(42x24x17 cm), with a maximum of five animals 
per cage, with daily hygiene, under controlled 
lighting conditions and light/dark cycle of 
12/12 hours. The animals were acclimatized in 
the laboratory for at least 1 h. All experiments 
were conducted between 11:00 h and 17:00 h 
in order to minimize possible circadian varia-
tions [22].
Very old and very young animals or those pre-
senting any disease that could affect the ener-
getic or contractile capacity were excluded.
Groups
The animals were randomly separated and dis-
tributed into seven groups of seven animals 
each: Group I (control – sterile saline solution), 
Group II (K3PO4-0.5 mg/kg), Group III (K3PO4-
1.5 mg/kg), Group IV (K3PO4-2.5 mg/kg), Group 
V (K3PO4-5.0 mg/kg), Group VI (K3PO4-7.5 mg/
kg) and Group VII (K3PO4-10.0 mg/kg). As 
shown, the difference between the groups is 
the amount of potassium phosphate adminis-
tered via rapid injection (for Groups II, III, IV, V, 
VI and VII), except for Group I, used as control 
and injected with sterile saline solution. In 
order to rule out the effect of animal handling 
or features of the vehicle used for drug admin-
istration, and to establish a base line for the 
analyses, the control group was injected with 
0.5 ml of sterile saline solution (NaCl 0.9%). 
It is important to emphasize that potassium 
phosphate is a substance widely used to con-
trol hypophosphatemia [23-27]. The amounts 
used in the experiments were based on the 
specifications given by Gaasbeek and Meinders 
[28], that used infusions of potassium phos-
phate at doses of 2.5 mg/kg. 
After inoculation, the animals were kept in their 
cages for 10 minutes prior to the surgical pro-
cedure for blood sampling, with no restriction 
to movement. A previous pilot experiment per-
formed by the authors showed that the concen-
trations of serum calcium, Pi, urea and creati-
nine were stable 10 minutes after the injection 
of different doses of K3PO4.
Surgical procedure
The animals were weighed and anesthetized 
with an intraperitoneal injection [29] of Sodium 
Pentothal 70 mg/kg (Anental®). They were con-
sidered anesthetized when there was no 
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response to mechanical stimuli and no move-
ment was observed after a painful stimulus - 
gripping the tail. The animals were placed on a 
metal tray in the supine position, with pelvic 
and thoracic limbs restrained by adhesive tape. 
A median longitudinal incision, of approximate-
ly 8 cm, was made in the abdominal region with 
fine scissors, with exposure and lateral spacing 
of the bowel to the right, allowing the visualiza-
tion of the inferior vena cava and withdrawal of 
venous blood, which was collected and condi-
tioned in tubes without coagulants and centri-
fuged to obtain the serum (Bio Eng® Serum 
Centrifuge, Model BE-5000 no 1616). The 
serum was separated from the cellular portion 
of the blood no later than twenty minutes after 
collection, avoiding ion exchanges between the 
two due to the increased permeability of eryth-
rocytes to calcium [30] and possible release of 
hematic phosphate [31], which could affect the 
results of the biochemical analysis. Hemolyzed 
blood samples were excluded from the bio-
chemical analysis.
Biochemical analysis
The concentrations of calcium, inorganic phos-
phate, urea and creatinine in the blood were 
measured threefold, and the biochemical val-
ues were used to represent the serum amounts 
of the substances. Blood samples were collect-
ed with Semi-automatic pipette (Digipet® 1000 
µl) and analyzed by the following methods:
Calcium: Cálcio-K007 (Bioclin®) - End point col-
orimetric test.
This is a colorimetric test for in vitro diagnostic, 
based on the measured of the intensity of color 
produced by the compound formed by o-cresol-
phthalein complexone and calcium in alkaline 
pH. The concentration of calcium can be calcu-
lated by measuring the absorbance of the sam-
ple [32]. More details about this technique can 
be found in [30].
Inorganic phosphate: Fósforo-K020 (Bioclin®) - 
End point colorimetric test.
This test is based on the reaction of Pi with 
ammonium molybdate, forming ammonium 
phosphomolybdate, which is subsequently 
reduced to molybdenum-blue - a blue sub-
stance, which the intensity of color is propor-
tional to the concentration of Pi [32]. By mea-
suring the absorbance of the samples it is 
possible to infer the concentration of Pi. A 
detailed description of the method is given by 
[31].
Creatinine: Creatinina-K0106 (Bioclin®) - End 
point colorimetric test (Jaffe modified).
It is a colorimetric test for in vitro diagnostic, 
based on the reaction of creatinine with picric 
acid, forming a reddish-yellow complex. In this 
pH occurs the maximum formation of the picric-
creatinine color complex. By adding the acid 
reagent, pH is reduced and the color due to cre-
atinine is undone, remaining the chromogens 
color [33]. The concentration of creatinine can 
be obtained by the difference between the 
absorbances at different pHs. A full description 
of the method can be found in [34].
Urea: Uréia Enzimática-K047 (Bioclin®) - End 
point enzymatic colorimetric test (Berthelot 
modified).
This test is based on the principle that urea can 
be hydrolyzed to ammonium ions and CO2 by 
urease (urea + 3H20 → 
urease 2NH4
+ + CO2 + 
2OH-). At alkaline pH and in the presence of 
salicylate and sodium hypochlorite, ammonia 
reacts and results in a compound of green 
color whose intensity is proportional to the con-
centration of urea in the sample [33]. Therefore, 
by measuring the absorbance of the samples it 
is possible to infer the concentration of urea. A 
full description of method the can be found in 
[35].
The study was approved by the Ethics 
Committee for Animal Experimentation of the 
Federal University of Minas Gerais, Brazil, 
according to Protocol #020.
Results
Dose-response curves were calculated for dif-
ferent doses of potassium phosphate versus 
the concentration of calcium, inorganic phos-
phate, urea and creatinine found in the plasma. 
The analyses of the dose-response curves were 
based on a graphical observation of the physi-
ological responses and trend analysis. The 
tests of hypotheses were based on the average 
concentration of the substances in the blood, 
followed by a further analysis of trends. Table 1 
shows the Linear (1-2) and Nonlinear (3-5) mod-
els tested for trend analyses.
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A model should be selected by taking into con-
sideration it’s fitting to the data and also to the 
objectives of the study. In other words, prior to 
any consideration, a model would be selected 
according to: a) the biological logics - the objec-
tive, the nature, the scope and extension of the 
study, and the expected results; b) the signifi-
cance of the adjustment of the model to the 
data; and c) the coefficient of determination 
(R2). If more than one model would apply - 
expressing a functional relationship between 
the studied variables and allowing an estimate 
of the parameters, capable of defining such 
relationship - the coefficient of determination 
and the biological logics expressed by them 
were was also considered in order to select the 
most suitable model. In so doing, the chosen 
model would not only be a good statistical 
model, but also would generate the best repre-
sentation of the biological aspects involved 
[36, 37].
Also, prior to the parametric analysis, each vari-
able was tested for normality, independence of 
errors and homoscedasticity. The following pro-
cedure was used: (1) Kolmogorov-Smirnov nor-
mality test [38]; (2) Hartley’s Fmax homosce-
dasticity test [39]; (3) Regression analyses with 
all models listed in Table 1; (4) Visual analysis 
of trends - adjustment of the model to the data, 
by means of a graph showing the mean values 
and errors.
After those tests and the preliminary graphic 
evaluation were concluded, it was found that all 
data could be represented by a normal distribu-
tion function (Calcium: K-S=0.12569, p< 0.20; 
Inorganic phosphate: K-S=0.167401, p< 0.15; 
Urea: K-S=0.11963, p< 0.20; Creatinine: 
K-S=0.16510, p< 0.15) and showed homoge-
neity of variance (Calcium: Fmax=2.9220, p< 
0.1382; Inorganic phosphate: Fmax=5.87, p< 
we compare the variation of the data obtained 
from the models and the total span of the real 
data, expressed by R2, it was found that three 
of models showed a better adjustment (qua-
dratic, sigmoidal and negative exponential). 
Nevertheless, the biological logic (the main cri-
terion of choice) is based on the assumption 
that there may be a stabilization of calcium pre-
cipitation with inorganic phosphate. When test-
ing such hypothesis, it was found that the sig-
moidal regression is the best model to support 
it.
The graph in Figure 1 represents the average of 
serum calcium for different doses of potassium 
phosphate. A reduction in the concentration of 
serum calcium can be observed as the doses 
of potassium phosphate increases up to 5.0 
mg/kg, with high statistically significant differ-
ences. Above that value, there is a tendency 
towards stabilization of the response, with no 
statistically significant differences, as shown in 
Table 3. The continuous line shows the tenden-
cy (trend) estimated by the sigmoidal model.
Table 3 shows the comparison between the 
mean values of serum calcium concentration 
for different doses of potassium phosphate. 
The values marked with ‘*’ are those that, 
according to the test, do not differ significantly, 
with a confidence level of 95%. Note that the 
control group (0.0 mg/kg of potassium phos-
phate) is significantly different from the others. 
The same can be seen for doses of 0.5, 1.5 and 
2.5 mg/kg. Doses of 5.0, 7.5 and 10.0 mg/kg 
are statistically similar to each other, meaning 
that the concentration of serum calcium must 
have reached a stable level at 5.0 mg/kg of 
injected potassium phosphate. This effect can 
also be observed in Figure 1.
A similar strategy was used to evaluate the cor-
relation between the doses of potassium phos-
phate and the concentration of inorganic phos-
Table 1. Linear and nonlinear regression models 
tested when searching for best-fit method for the 
dose-response curves
1 Linear yi=y0+ax
2 Quadratic yi=y0+ax+bx
2
3 Negative exponential yi=ae
-bx
4 Negative exp. of three parameters yi=y0+ae
-bx
5 Sigmoidal of four parameters
1
y y
e
a
| b
x x |0 0i
= +
+ -
-
0.10; Urea: Fmax=2.2987, p< 0.1803; 
Creatinine: Fmax=4.25, p< 0.10).
Serum calcium concentration
Table 2 shows the estimated values for 
each parameter of the models, adjusted to 
the dose-response curve of serum calcium, 
according to the criteria described earlier. 
Note that all models show a good adjust-
ment to the data (p< 0.05). However, when 
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phate, urea and creatinine in the plasma. The 
final results as shown next.
Although the data from urea analyses show a 
normal distribution and homogeneity of vari-
ance, none of the tested regression models 
showed statistical significance to represent the 
changes of urea as a function of the dosage of 
inorganic phosphate. Also, no statistically sig-
nificant differences were found between differ-
ent doses of potassium phosphate, with a con-
fidence level of 95%. Figure 3 shows the 
average of serum urea for different doses of 
potassium phosphate.
Serum creatinine concentration
In the same way as for urea, although the cre-
atinine analyses showed a normal distribution 
and homogeneity of variance, none of the test-
ed regression models showed statistical signifi-
Table 2. Estimated values for the parameters of the mathematical models, calculated for the serum 
calcium x potassium phosphate dose-response
Regression model Y0 a b x0 R
2 R2aj. p
Linear 7.9430 -0.3180 0.7579 0.7095 0.0108
Quadratic 8.6239 -0.9604 0.0662 0.9841 0.9761 0.0003
Negative exponential 8.1247 0.0539 0.8090 0.7708 0.0058
Neg. exp. of three parameters 5.2387 3.5702 0.4046 0.9629 0.9444 0.0014
Sigmoidal of four parameters 5.3532 4.0662 -1.1411 1.5231 0.9744 0.9489 0.0069
Figure 1. Relationship between doses of potassium phosphate (mg/kg) and 
serum calcium (mg/dl) and the trend line (four-parameter sigmoidal model).
Serum inorganic phos-
phate concentration
Figure 2 shows the average 
concentration of inorganic 
phosphate (Pi) found in the 
blood for different doses of 
potassium phosphate. An 
increase in the concentra-
tion of Pi can be observed 
as the doses of potassium 
phosphate increases up to 
2.5 mg/kg, with high statis-
tically significant differenc-
es. Above that value, there 
is a tendency towards stabi-
lization of the response, 
with no statistically signifi-
cant differences, as shown 
in Table 4. The continuous 
line shows the tendency 
(trend) estimated by the 
sigmoidal model.
Serum urea concentration
Table 3. Results of the Tukey test comparing 
the mean serum calcium (mg/dl) with different 
doses of potassium phosphate (mg/kg)
Potassium phosphate (mg/kg) Serum calcium (mg/dl)
0.0 8.73
0.5 7.99
1.5 7.36
2.5 6.77
5.0 5.22*
7.5 5.37*
10.0 5.57*
Values marked with ‘*’ do not differ significantly, with confi-
dence level of 95%.
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cance to represent the changes in serum con-
centration as a function of the dosage of 
inorganic phosphate. No statistically significant 
differences were found between different 
doses of potassium phosphate, with a confi-
dence level of 95%. Figure 4 shows the average 
of serum creatinine for different doses of potas-
sium phosphate.
Discussion
In this paper we have described a method for in 
vivo precipitation of calcium phosphate by 
analyses of blood collected from the inferior 
vena cava of the animals. Although we did not 
performed in vitro experiments, it is assumed 
that the precipitation of calcium phosphate 
occurred in a similar manner to the reactions 
reported by other in vitro experiments described 
in the literature [12, 16, 17].
The results show that injection of potassium 
phosphate raises the concentration of inorgan-
ic phosphate in the blood for doses up to 2.5 
mg/kg - higher doses have no significant impact 
in the concentration of serum Pi. The amount of 
serum calcium was substantially reduced after 
the injection of potassium phosphate. Such 
reduction also varied according to the dosage 
of potassium phosphate, with no statistically 
significant changes for doses above 5.0 mg/kg. 
We assume that the dose-response has 
reached a certain metabolic equilibrium at 5.0 
mg/kg. Confirming this assertion, the tests of 
trend analysis showed that the concentrations 
of serum calcium in response to inoculation of 
doses of 5.0, 7.5 and 10.0 mg/kg of potassium 
phosphate were basically the same (Figure 1, 
Table 3). When comparing the responses of cal-
cium concentration between the control group 
(0.0 mg/kg of potassium phosphate) and the 
Figure 2. Relationship between doses of potassium phosphate (mg/kg) and 
serum Pi (mg/dl) and the trend line (four-parameter sigmoidal model).
Table 4. Results of the Tukey test compar-
ing the mean serum Pi (mg/dl) for different 
doses of potassium phosphate (mg/kg) 
Potassium phosphate (mg/ kg) Serum Pi (mg/dl)
0.0 4.72
0.5 5.10
1.5 6.10
2.5 6.82*
5.0 7.06*
7.5 6.49*
10.0 6.66*
Values marked with ‘*’ do not differ significantly, with 
confidence level of 95%.
means of potassium phos-
phate inoculation. Unlike 
the in vitro approach, pre-
dominant for this kind of 
experiment, the method 
allowed us to avoid the 
omission of substances 
that could play important 
roles during in vivo experi-
ments, as described earlier. 
Also, the injection of potas-
sium phosphate can be 
done with minor effects on 
other physiological vari-
ables that could affect the 
desired results, allowing a 
new spectrum of research-
es to better understand the 
processes of muscle con-
traction and muscle fatigue. 
The experimental setup 
consisted on the intraperi-
toneal injection of different 
doses of potassium phos-
phate and biochemical 
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experimental Group V (5.0 mg/kg - promoter of 
the maximum effect, as shown in Table 3), a 
highly significant difference was observed.
By proving a method to induce the precipitation 
of calcium phosphate in live animals and defin-
ing and ideal dose to do so (5.0 mg/kg in rats), 
Figure 3. Relationship between doses of potassium phosphate (mg/kg) and 
serum urea (mg/dl).
Figure 4. Relationship between doses of potassium phosphate (mg/kg) and 
serum creatinine (mg/dl).
Another important result 
gathered with this study 
was that the injection of 
potassium phosphate, at 
doses up to 10 mg/kg, did 
not have any significant im-
pact in important metabolic 
functions during the experi-
ments. It is known that cha-
nges in urea and creatinine 
may indicate abnormal fun-
ctioning of the urinary sys-
tem and protein metabo-
lism [40]. Although there is 
some debate on the effi-
ciency of those markers as 
indicators of premature ren- 
al damage, it is a consen-
sus that high concentration 
of those substances in the 
plasma may indicate a vari-
ety of renal dysfunctions 
and damage [40, 41]. One 
might rightfully wonder whe- 
ther high levels of urea co-
uld also be the result of the 
degradation of exogenous 
proteins from a feeding pro-
cess. However, that was 
not the case of this study, 
since the animals were ke- 
pt fasting prior to the exper-
iments. High levels of cre-
atinine could also be the 
result of intense physical 
activity or muscular lesions 
[42, 43], but again, to avoid 
such effect, the animals 
were not stressed prior to 
the experiments. Therefore, 
the absence of changes in 
the concentration of serum 
urea and creatinine (Fig-
ures 3 and 4) indicates that 
the injection of potassium 
phosphate did not have 
major effects on physiologi-
cal variables that could be 
traced by urea or creati-
nine, for the duration of the 
experiments.
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we hope to provide a novel research tool for 
studying the role of inorganic phosphate and 
calcium concentration in various physiological 
processes, in particular, those related to skel-
etal muscle fatigue. 
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